TORONTO, Aug. 17, 2011 /PRNewswire/ - Biosign Technologies Inc. (TSXV: BIO, the "Company") announces that its Annual General Meeting of
Shareholders will be held at the office of Goodmans LLP, Suite 3400,
Bay Adelaide Centre, 333 Bay Street, Toronto, Ontario, on September 12,
2011 at 11:00 a.m. (Toronto time) (the "Meeting") for the following
to receive the audited financial statements of the Company for the
fiscal year ended December 31, 2010 with auditor's report thereon;
to fix the number of directors at six and to elect six directors for the
to appoint the Company's auditor for the ensuing year;
to confirm and reapprove the Company's "rolling 10%" stock option plan,
as more particularly described in the accompanying Information
to transact such other business as may properly come before the Meeting
or any adjournment thereof.
Steven Bloom is proposed to be a director in addition to the current
five directors. Steven A. Bloom, a well-regarded accountant, is
nominated to join the board and, if elected, is anticipated to Chair
the Audit Committee. Mr. Bloom is currently the Senior Vice President,
Finance for Kilmer Van Nostrand Co. Limited and has held positions as
Chief Financial Officer at several private and public companies. Mr.
Bloom obtained his Chartered Accountant and Certified Public Accountant
and holds an Honours of Business Administration degree from the Richard
Ivey School of Business at the University of Western Ontario.
Only shareholders of record at the close of business on August 8, 2011
will be entitled to receive notice of, and to vote at, the Meeting or
any adjournment thereof. Shareholders who are unable to or who do not
wish to attend the Meeting in person are requested to date and sign the
enclosed Proxy form promptly and return it in the self-addressed
envelope enclosed for that purpose or by any of the other methods
indicated in the Proxy form. To be used at the Meeting, proxies must be
received by Computershare Investor Services Inc., Proxy Department, 100
University Avenue, 9th Floor, Toronto, Ontario M5J 2Y1 by no later than
11:00 a.m. (Toronto time) on September 8, 2011 or, if the Meeting is
adjourned, by no later than 11:00 a.m. (Toronto time) on the second
last business day prior to the date on which the Meeting is reconvened,
or may be deposited with the chairman of the Meeting prior to the
commencement of the Meeting. If a registered shareholder receives more
than one Proxy form because such shareholder owns shares registered in
different names or addresses, each Proxy form should be completed and
The related documents (Notice of Meeting, Information Circular, Proxy
Form and Return Card) are available from SEDAR or the company's website
About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Key
applications include intelligent systems for noninvasive monitoring of
common health risks associated with blood pressure, glucose, and
medication. The core technology combines measurement, analysis, and
rapid knowledge formation to support health monitoring across global
markets. The UFIT® medical device technology powers quality data
collection and analytics for clinical diagnostics, self-care, wellness,
disease state evaluation & management, and remote patient monitoring.
For more information on Biosign, please visit www.biosign.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
SOURCE Biosign Technologies Inc.